Fig. 2From: China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapyThe review process of anlotinib. NDA, new drug application; CMC, chemistry manufacture control; RMP, risk management programBack to article page